Bosutinib Monohydrate
The monohydrate salt form of bosutinib, a BCR-ABL tyrosine kinase inhibitor used in chronic myelogenous leukemia. It inhibits the abnormal kinase that drives leukemic cell proliferation. It is taken orally with food to reduce stomach-related side effects.
Molecular Weight
548.5000 g/mol
TPSA
83.90 Ų
Therapeutic Areas
Mechanism of Action
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …
2D Structure
Cite this structure
Embed this structure
SMILES
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
InChI
InChI=1S/C26H29Cl2N5O3.H2O/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27;/h11-14,16H,4-10H2,1-3H3,(H,30,31);1H2
Molecular Formula
C26H31Cl2N5O4
HBD / HBA
2 / 9
Rotatable Bonds
9
Heavy Atoms
37
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
The monohydrate salt form of bosutinib, a BCR-ABL tyrosine kinase inhibitor used in chronic myelogenous leukemia. It inhibits the abnormal kinase that drives leukemic cell proliferation. It is taken orally with food to reduce stomach-related side effects.
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.
Yes, Bosutinib Monohydrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2095206. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11990828. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bosutinib-monohydrate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bosutinib-monohydrate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bosutinib-monohydrate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bosutinib-monohydrate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bosutinib-monohydrate"></drugfyi-drug>